Florida has made notable strides in the realm of pharmaceutical legislation with recent proposals for new pharmacy benefit manager rules. As reported here, on September 18, 2023, the Florida Office of Insurance Regulation (OIR) published proposed rules to implement provisions of the Prescription Drug Reform Act (Florida Senate Bill 1550), which specifically govern Pharmacy Benefit Managers (PBMs).
The Prescription Drug Reform Act is significant because it mandates that all PBMs become licensed as an Administrator with the OIR to maintain legal operational status within the state after December 31, 2023. The major shift towards obligatory licensing is deemed to be a step forward to enhance the regulation of PBMs across Florida.
This development follows a consistent national trend of states designing regulatory frameworks for PBMs. Many legal professionals working in business environments may recall similar initiatives from states such as Ohio, Arkansas, and Maryland, just to mention a few.
The consequences of these rules being proposed could be significant, potentially inciting changes in the business and operational strategies of PBMs. Moreover, companies intending to establish PBMs or expand their PBM operations in Florida, would need to consider the implications of such regulatory adjustments, especially as it regards licensing.
While the exact outcomes of the proposed rules remain uncertain, what is undeniable is that changes are afoot within the pharmaceutical sector and the workings of PBMs. Only time will provide a clear picture of the full ramifications of these proposed rules.